Gori N, Chiricozzi A, Malvaso D, et al. - In patients with an inadequate response to dupilumab, researchers evaluated the efficacy and safety of dupilumab in combination with systemic agents or phototherapy. Researchers included patients aged >18 years with moderate-severe atopic dermatitis (AD), under treatment with dupilumab in this retrospective, monocentric, observational study. They examined data of individuals who experienced an inadequate response to dupilumab, even when combined with topical corticosteroids, and for whom an additional systemic treatment or phototherapy was combined to dupilumab. A total of 69 patients treated with dupilumab were included in the study. This research indicates that the combination of dupilumab with a conventional drug or phototherapy may represent a valid therapeutic choice, maintaining a good safety profile in AD patients not responding fully to dupilumab monotherapy. Most patients (11 of 12) saw an improvement of signs and symptoms of AD overall following 8 weeks of combined therapy,